Long-Term Safety and Effectiveness of Canakinumab in Patients with MKD/HIDS: Interim Analysis of the RELIANCE Registry
Abstract Introduction Interim analysis of the long-term safety and effectiveness of canakinumab, at a patient level, in the mevalonate kinase deficiency/hyperimmunoglobulin-D syndrome (MKD/HIDS) cohort of the RELIANCE registry. Methods From June 2018, the RELIANCE registry enrolled paediatric (aged ...
Saved in:
Main Authors: | Prasad T. Oommen, Tilmann Kallinich, Juergen Rech, Norbert Blank, Julia Weber-Arden, Jasmin B. Kuemmerle-Deschner |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2024-12-01
|
Series: | Rheumatology and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s40744-024-00733-7 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01) -
Autoimmune/autoinflammatory syndrome induced by adjuvants: what is it and why the controversy?
by: Sajal Ajmani
Published: (2019-01-01) -
Synthetic inhibition of SREBP2 and the mevalonate pathway blocks rhabdomyosarcoma tumor growth in vitro and in vivo and promotes chemosensitization
by: Silvia Codenotti, et al.
Published: (2025-02-01) -
Mortality in Antinuclear Antibody-Positive Patients with and Without Rheumatologic Immune-Related Disorders: A Large-Scale Population-Based Study
by: Uria Shani, et al.
Published: (2025-01-01) -
MVK, induced by Kras, represses cGAS-Sting signalling in lung adenocarcinoma
by: Changsheng Zhou, et al.
Published: (2025-01-01)